论文信息 - Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. - 字舞流文

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

C. Dooms | A. Drilon | E. Felip | R. Dziadziuszko | V. Velcheti | D. Camidge | B. Cho | Sang-We Kim | N. Yang | M. Krebs | F. Ades | A. D. de Langen | Shun Lu | P. Cheema | Jessica J. Lin | B. Solomon | S. Stopatschinskaja | D. Trone | D. M. MORO SIBILOT | S. Kao